RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
RenovoRx today announced continued commercial progress, with 12 U.S. cancer centers now utilizing the RenovoCath device. These 12 centers are in addition to those centers currently using RenovoCath as part of RenovoRx’s ongoing Phase III trial.